All Cases

Non-malignant Hematology

Mapped key decisions and drivers of adoption for a blockbuster hematology product, informing strategic planning at a large pharmaceutical company looking to expand to new indications

Analyzed a market entry strategy for a large, global pharmaceutical company to ensure it aligned with expected capacity and could be supported by its expected economic impact

Market and patient access scenario planning for a pipeline hemophilia asset

State Medicaid coverage assessment for a novel hemophilia drug

Characterized the KOL and CoE Landscape for a pediatric dysregulation syndrome to support pre-commercialization planning at a mid-sized pharmaceutical company